Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin for prevention of contrast-induced nephropathy in chronic kidney disease
IRCT20090905002417N21Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jan 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in contrast-induced nephropathy (CIN) comparing Rosuvastatin with Placebo (2 arms). Primary endpoint: Serum creatinine change. Started Jan 2018; status: completed.
02
Drugs
rosuvastatin
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on IRCT20090905002417N21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090905002417N21.